Last Updated: November 16, 2026

Investigational Drug Information for Ciraparantag

« Back to Dashboard


What is the development status for investigational drug Ciraparantag?

Ciraparantag is an investigational drug.

There have been 4 clinical trials for Ciraparantag. The most recent clinical trial was a Phase 2 trial, which was initiated on May 8th 2017.

The most common disease condition in clinical trials is [disabled in preview]. The leading clinical trial sponsors are Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., Perosphere, Inc., and [disabled in preview].

There are eighteen US patents protecting this investigational drug and fifty-three international patents.

Recent Clinical Trials for Ciraparantag
TitleSponsorPhase
Study of Ciraparantag for Reversal of Anticoagulation Induced by Apixaban or Rivaroxaban in Healthy AdultsPerosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Phase 2
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCTPerosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.Phase 2
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCTPerosphere, Inc.Phase 2

See all Ciraparantag clinical trials

Clinical Trial Summary for Ciraparantag

Top disease conditions for Ciraparantag
Top clinical trial sponsors for Ciraparantag

See all Ciraparantag clinical trials

US Patents for Ciraparantag

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ciraparantag ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
Ciraparantag ⤷  Start Trial Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors ⤷  Start Trial
Ciraparantag ⤷  Start Trial Oral drug dosage form comprising various release profiles Triastek Inc ⤷  Start Trial
Ciraparantag ⤷  Start Trial Thermally responsive anti-sag agents Halliburton Energy Services Inc ⤷  Start Trial
Ciraparantag ⤷  Start Trial Rapidly-orodispersible tablets having an in interior cavity Aprecia Pharmaceuticals LLC ⤷  Start Trial
Ciraparantag ⤷  Start Trial Thermally responsive lost circulation materials Halliburton Energy Services Inc ⤷  Start Trial
Ciraparantag ⤷  Start Trial Engineered platelets for targeted delivery of a therapeutic agent Jpv01 Ltd ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ciraparantag

Drugname Country Document Number Estimated Expiration Related US Patent
Ciraparantag Australia AU2017261372 2036-05-05 ⤷  Start Trial
Ciraparantag Canada CA3023278 2036-05-05 ⤷  Start Trial
Ciraparantag China CN107847398 2036-05-05 ⤷  Start Trial
Ciraparantag European Patent Office EP3452003 2036-05-05 ⤷  Start Trial
Ciraparantag European Patent Office EP3981392 2036-05-05 ⤷  Start Trial
Ciraparantag Hong Kong HK1249728 2036-05-05 ⤷  Start Trial
Ciraparantag Japan JP2019520866 2036-05-05 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.